Transcription 6 transcripts have been described for this gene (4 with protein product, 2 with no protein product): SLC16A1-001 (5 exons; 3910 bps transcript length; 500 residues translation length); SLC16A1-002 (5 exons; 2101 bps transcript length; 456 residues translation length); SLC16A1-003 (4 exons; 865 bps transcript length; 215 residues translation length); SLC16A1-004 (2 exons; 452 bps transcript length; no translation product); SLC16A1-005 (4 exons; 1099 bps transcript length; 296 residues translation length); SLC16A1-006 (2 exons; 430 bps transcript length; no translation product).
Pseudogene
1 related pseudogene identified -AKR7 family pseudogene (AFARP1), non-coding RNA.
Protein
Description 500 amino acids; 53958 Da; 12 transmembrane domains, intracellular N-and C-terminal and a large intracellular loop between transmembrane domains 6 and 7.
Expression
Ubiquitous.
Localisation
Plasma membrane; also described in rat mitochondrial and peroxisomal membranes.
Function
Catalyses the proton-linked transport of metabolically important monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and ketone bodies (acetoacetate, betahydroxybutyrate and acetate).
Protein diagram drawn following UniProtKB/Swiss-Prot database prediction, using TMRPres2D software.
Implicated in

Various cancers
Note MCT1/SLC16A1 has been described to be upregulated in a variety of tumours. Disease High grade glial neoplasms (Mathupala et al., 2004; Fang et al., 2006) , colorectal (Koukourakis et al., 2006; , lung (Koukourakis et al., 2007) , cervical , and breast carcinomas (Pinheiro et al., in Press) .
Breast cancer
Prognosis
In breast cancer, MCT1/SLC16A1 was found to be associated with poor prognostic variables such as basallike subtype and high grade tumours (Pinheiro et al., in Press) . Oncogenesis SLC16A1 is expressed in normal breast tissue, but is silenced in breast cancer due to gene methylation (Asada et al., 2003) .
Gastric cancer
Note
The prognostic value of CD147 (a MCT1/SLC16A1 and MCT4/SLC16A3 chaperone required for plasma membrane expression and activity) was associated with MCT1/SLC16A1 co-expression in gastric cancer cells (Pinheiro et al., 2009) . Prognosis Co-expression of MCT1/SLC16A1 with CD147 was associated with advanced gastric carcinoma, Lauren's intestinal type, TNM staging and lymph-node metastasis, in gastric cancer.
Colorectal carcinoma
Note MCT1/SLC16A1 has been described to be downregulated in colorectal carcinoma (Lamber et al., 2002) . Note Merezhinskaya et al. (2000) identified two heterozygous transitions in the SLC16A1 gene, in patients with erythrocyte lactate transporter defect: 610A-G transition (resulting in a lys204-to-glu (K204E) substitution in a highly conserved residue) and 1414G-A transition (resulting in a gly472-to-arg (G472R) substitution halfway along the cytoplasmic Cterminal chain). These substitutions are not conserved, but were not identified in 90 healthy control individuals. Erythrocyte lactate clearance in patients with these mutations was 40 to 50% that of normal control values.
Erythrocyte lactate transporter defect
Hyperinsulinemic hypoglycemia familial 7
Note Otonkoski et al. (2007) identified two heterozygotic alterations in the SLC16A1, in affected members of a Finnish family segregating autosomal dominant exercise-induced hyperinsulinemic hypoglycemia. First, a 163G-A transition in exon 1 located within a binding site for nuclear matrix protein-1 and predicted to disrupt the binding sites of 2 potential transcriptional repressors, and, secondly, a 25-bp insertion at nucleotide -24 introducing additional binding sites for the ubiquitous transcription factors SP1, USF and MZF1. The first variation leads to a 3-fold increase in transcription while the second variation leads to a 10-fold increase in transcription. These mutations were not found in 92 Finnish and German controls.
